AstraZeneca PLC (LON:0A4J)

Market Cap	196.16B
Revenue (ttm)	41.24B
Net Income (ttm)	6.05B
Shares Out	n/a
EPS (ttm)	3.87
PE Ratio	32.40
Forward PE	17.50
Dividend	0.88 (1.19%)
Ex-Dividend Date	Aug 8, 2025

Volume	745
Average Volume	6,939
Open	83.96
Previous Close	n/a
Day's Range	83.96 - 83.96
52-Week Range	62.79 - 83.96
Beta	0.18
RSI	65.17
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4J

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD